BackFirst Tracks Biotherapeutics Overview

First Tracks Biotherapeutics Long Term Debt

First Tracks Biotherapeutics's long-term debt is $1.9M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$1.90M

Peer trimmed avg / median

Loading

First Tracks Biotherapeutics Long Term Debt History

Loading

First Tracks Biotherapeutics vs. peers: Long Term Debt Comparison

Loading

First Tracks Biotherapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

First Tracks Biotherapeutics (TRAX) FAQ

First Tracks Biotherapeutics posts a long-term debt of $1.9M as of June 2026. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Long-Term Debt is one piece of First Tracks Biotherapeutics's financial statement story. At $1.9M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for TRAX's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; First Tracks Biotherapeutics's other metric pages and overview cover the third.

Judging First Tracks Biotherapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $1.9M here, then scan peer and history charts to see if the gap is persistent.